Therefore, it is not surprising that the initial endeavour to translate immune tolerance in MS clinical practice revolved around the oral administration of whole bovine myelin, comprising both MBP and proteolipid protein (PLP). The gene discussed is MBP; the disease is myeloid sarcoma.